ISM8969 first-in-human: can an NLRP3 inhibitor reach the brain?
Insilico and Hygtia dosed the first participant with ISM8969 on June 17; Phase I in Australia will test safety and whether this NLRP3 inhibitor actually reaches the brain.
On June 17, Insilico Medicine reported that the first participant received ISM8969 in a Phase I clinical trial in Australia. The molecule blocks the NLRP3 inflammasome, a protein complex of the innate immune system that, when chronically active, triggers inflammatory signals (IL-1β, IL-18) linked to age-related inflammation, tissue damage, and neurodegeneration.
The protocol (NCT07581431) enrolls healthy adults, one cohort aged 65 to 80, and people with obesity, elevated hsCRP (a marker of systemic inflammation), and cardiovascular risk factors. People with a history of central nervous system disease are excluded. Parkinson's disease remains a potential target for future development stages.
The strongest design element is cerebrospinal fluid sampling: it will show whether ISM8969 actually crosses the blood-brain barrier. For a neuroinflammation drug, this is an early filter. Blood levels are straightforward to measure; brain exposure has to be proven separately.
In January, Insilico received FDA IND clearance (permission to begin human trials) and signed a deal with Hygtia Therapeutics: the parties split global rights 50/50, Insilico leads the regulatory filing and Phase I, and Hygtia is expected to take over later clinical stages and commercialization. Insilico may receive up to $66 million in upfront and milestone payments. The company credits Chemistry42, its generative chemistry platform, with optimizing the molecule for blood-brain barrier penetration.
Other NLRP3 inhibitors are already in the clinic. NodThera is advancing NT-0796, another oral inhibitor; in 2025, Movement Disorders published data from Parkinson's patients showing that 28 days of therapy reduced markers of neuroinflammation and systemic inflammation. ISM8969 is the first-in-human dose for this molecule and the first clinical step for the Insilico/Hygtia partnership.
Open the related Eternal Search page
Sources
insilico.com
clinicaltrials.gov
t.me
pubmed.ncbi.nlm.nih.gov
ISM8969 is the week's concrete NLRP3 milestone, but the news naturally raises the upstream question of what chronically activates the inflammasome during aging. Senescent cells and their SASP are the mechanistic answer, making Cleara a directly relevant parallel on the same cascade; the Eternal Search page gives readers a way to compare both intervention points side by side.